Genespire announces that GENE202 has been granted Orphan Drug Designation by the FDA and EC for the treatment of methylmalonic acidemia

da genespire | Gen 20, 2026 | Notizie

Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting

da genespire | Mag 14, 2025 | Notizie

Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA

da genespire | Mag 8, 2025 | Notizie

The AstraZeneca acquisition of EsoBiotec – important validation for Genespire’s lentiviral vector platform

da genespire | Mar 31, 2025 | Notizie

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic

da Harry Fowler | Set 25, 2024 | Notizie

Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting

da Harry Fowler | Mag 9, 2024 | Notizie